CD8A and neoplasm: The finding that treatment of mice with HDC did not trigger a significant influx of CD8+ T cells into tumors suggests that combining HDC and α-PD-1/α-PD-L1 therapy with agents that enhance T cell infiltration, such as chemotherapy or α-VEGF antibodies [30, 31], might further improve anti-tumor efficacy.